There are no studies documenting the percentage of doctors taking the drugs. But physicians “are a good litmus test for drugs ...

Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era ...

Regeneron's 2025 outlook includes defensive capital allocation, competitive pressure on Eylea, et cetera. Click here to read ...

Regeneron reported Q4 2024 earnings today and declared its first-ever dividend of $0.88 per quarter. Click here to know what ...

Head of Investor Relations Welcome to the Q4 and full year 2024 conference call for investors and analysts. As usual, you can find the slides on sanofi.com. Please turn to Slide 3. Here we have the ...

Sanofi (NASDAQ:SNY) reported robust financial results for the fourth quarter of 2024, driven by significant sales growth and a solid increase in earnings per share (EPS). The company's net sales rose ...

To play this video you need to enable JavaScript. Watch Bailey perform her song Cobalt Blue by the sea. Bailey talks about living in St Ives and becoming a musician. What is the meaning of the ...

Last year ended with warnings about malicious websites parting holiday shoppers with their hard earned cash, and 2025 has started the same. This time it’s more specific than the unprecedented fraud we ...

The CEO discussed the success of Dupixent and the remarkable achievement of over $13 billion in global sales in 2024, highlighting its commercial advantage and setting a milestone for Sanofi.

The sum-of-the-parts way and the platform way. Regeneron has 11 approved drugs but two comprise most of the cash flows. The two are Eylea and Dupixent.

We recently compiled a list of the 9 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against the other ...

Fresh off the release of My Way, Yola stopped by CBS Mornings’ Saturday Sessions to showcase of tracks from the new EP. Yola and her band performed three songs — “Temporary,” “Future ...